CD38 and neoplasm: ISB 1442 is a fully human bispecific antibody that targets CD38 and CD47 that is designed to kill CD38-expressing tumor cells through multiple immune-mediated mechanisms via the blocking of SIRPα, the CD47-signal regulatory protein which leads to increased complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and antibody-dependent cellular phagocytosis (71).